About Regenerative Medical Technology Group Inc
- Industry: Retail
- Exchange: OTC MARKETS
- Country: US
- Website: https://regenmedtechgroup.com/
Frequently Asked Questions
What is the 52-week range for RMTG?
The 52-week high is $0.125 and the 52-week low is $0.0189.
What is the P/E ratio for RMTG?
The P/E ratio data is currently unavailable.
What is the dividend yield for RMTG?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
ROE data is currently unavailable.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -101.21%.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Latest RMTG News
RMTG Expands Peptide Education Platform With ISSCA Peptide Certification 2.0 and New Physician Reference Guides
The upgraded program complements Cellgenic's expanding peptide training product portfolio and is intended as a current example of RMTG's education-to-product operating model.MIAMI, FL / ACCESS Newswire / October 1, 2026 / Oct 1, 2026, Inc.
RMTG's ISSCA Division to Host ISSCA 125 Global Summit in Cancún, Mexico
Training Business Accelerates with Hundreds of Physicians from over 50 Countries at our Flagship Cancún Global Summit. ISSCA 125 Global Summit is scheduled to combine five ISSCA certification tracks and an international scientific conference under one program, as part of the Company's physician-education activities conducted through Global Stem Cells Group.
RMTG's ISSCA Division Launches Integrative Fellowship in Point-of-Care Regenerative Medicine through ISSCA AI(TM) Strategy
ISSCA's most comprehensive credential to date integrates regenerative medicine, biotechnology, longevity medicine, and artificial intelligence - a durable, multi-year physician-relationship asset. New multi-component fellowship is designed to combine regenerative medicine, biotechnology, longevity medicine, clinical implementation, and physician-controlled clinical-intelligence tools offered through ISSCA AI™.
Regenerative Medical Technology Group, Inc. Details Expanded ISSCA AI(TM) Clinical Intelligence Platform, Including Protocol-Native Engine, Structured Data Assets, and Multi-Line Commercial Model
Physician-controlled lab-to-plan workflow, ISSCA protocol ingestion, licensed technology partnership, and clinic-facing SaaS and membership design - with the physician remaining the decision-makerMIAMI, FL / ACCESS Newswire / September 14, 2026 / , Inc. (the "Company" or "RMTG") (OTCID:RMTG), operating through its wholly owned subsidiary Global Stem Cells Group, today issued an expanded technology, data, and commercial overview of the ISSCA AI™ Clinical Intelligence Platform.
RMTG's Cellgenic Division Begins Local Commercial Activity in Colombia, Subject to Colombian Regulatory Requirements
Colombia is the third Latin American market in which Cellgenic has recently announced local commercial arrangements. Activity remains subject to applicable Colombian law and the terms of local contracts.